All trials
NCT05834296PHASE1ACTIVE NOT RECRUITING

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

✨ Plain-English version on the way · ~2 days

We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:

ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.
Read full record on ClinicalTrials.gov

Eligibility check — Phoenix members

Phoenix members see for THIS trial:

  • APOE genotype match
  • Cognitive status fits inclusion
  • Specific exclusions flagged
  • Distance to nearest site
Check my eligibility — become a member
Sites
1 location
Start
2023-07-05

Interventions tested

  • BIOLOGICALALZN002 (autologous DCs pulsed with E22W mutant peptide).
  • DRUGPlacebo
View full record on ClinicalTrials.gov

We use cookies to enhance your experience.